Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients with Coronary Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines

Circulation

Volumn 134, Issue 10, 2016, Pages e156-e178

  Bittl, John A ^a   Baber, Usman ^a   Bradley, Steven M ^a   Wijeysundera, Duminda N ^a  

^a NONE

Author keywords

acute coronary syndrome; AHA Scientific Statements; aspirin; coronary artery disease; coronary stents; dual antiplatelet therapy (DAPT); focused update; P2Y12 inhibitor; stable ischemic heart disease

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; TICAGRELOR; PURINERGIC P2Y RECEPTOR ANTAGONIST;

ARTICLE; BAYES THEOREM; BLEEDING; CAUSE OF DEATH; CORONARY ARTERY DISEASE; CORONARY RISK; DRUG ELUTING CORONARY STENT; DUAL ANTIPLATELET THERAPY; HEART DISEASE; HEART INFARCTION; HUMAN; INTENTION TO TREAT ANALYSIS; LONG TERM CARE; MEDICAL SOCIETY; META ANALYSIS; MORTALITY RATE; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK BENEFIT ANALYSIS; SECONDARY PREVENTION; STENT THROMBOSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; ADVERSE EFFECTS; ADVISORY COMMITTEE; CARDIOLOGY; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG ELUTING STENT; HEMORRHAGE; PROCEDURES; RESEARCH; STANDARDS; THROMBOSIS; TIME FACTOR; UNITED STATES;

ADVISORY COMMITTEES; AMERICAN HEART ASSOCIATION; ASPIRIN; CARDIOLOGY; CORONARY ARTERY DISEASE; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; DRUG-ELUTING STENTS; HEMORRHAGE; HUMANS; PLATELET AGGREGATION INHIBITORS; PRACTICE GUIDELINES AS TOPIC; PURINERGIC P2Y RECEPTOR ANTAGONISTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH REPORT; THROMBOSIS; TIME FACTORS; UNITED STATES;

EID: 84961967562     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIR.0000000000000405     Document Type: Article

References (72)

1. Levine GN, Bates ER, Blankenship JC, et al. 2011 ACCF/AHA/ SCAI guidelines for percutaneous coronary intervention: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. Circulation. 2011;124:e574-651
2. Mehta SR, Yusuf S, Peters RJ, et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001;358:527-33
3. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357:2001-15
4. Wallentin L, Becker RC, Budaj A, et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57
5. Grines CL, Bonow RO, Casey DE Jr, et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents: a science advisory from the American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, and American Dental Association, with representation from the American College of Physicians. Circulation. 2007;115:813-8
6. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long-term clinical outcomes after drug-eluting stent implantation. JAMA. 2007;297:159-68
7. Pfisterer M, Brunner-Rocca HP, Buser PT, et al. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006;48:2584-91
8. Palmerini T, Biondi-Zoccai G, Della Riva D, et al. Clinical outcomes with bioabsorbable polymer versus durable polymer-based drugeluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2014;63:299-307
9. Baber U, Mehran R, Sharma SK, et al. Impact of the everolimuseluting stent on stent thrombosis: a meta-analysis of 13 randomized trials. J Am Coll Cardiol. 2011;58:1569-77
10. Camenzind E, Wijns W, Mauri L, et al. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimuseluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet. 2012;380:1396-405
11. Mauri L, Hsieh WH, Massaro JM, et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med. 2007;356:1020-9
12. Park S-J, Park D-W, Kim Y-H, et al. Duration of dual antiplatelet therapy after implantation of drug-eluting stents. N Engl J Med. 2010;362:1374-82
13. Lee CW, Ahn J-M, Park D-W, et al. Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Circulation. 2014;129:304-12
14. Valgimigli M, Campo G, Monti M, et al. Short-versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial. Circulation. 2012;125:2015-26
15. Palmerini T, Benedetto U, Bacchi-Reggiani L, et al. Mortality in patients treated with extended duration dual antiplatelet therapy after drug-eluting stent implantation: a pairwise and Bayesian network meta-analysis of randomised trials. Lancet. 2015;385:2371-82
16. Gwon H-C, Hahn J-Y, Park KW, et al. Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study. Circulation. 2012;125:505-13
17. Kim B-K, Hong M-K, Shin D-H, et al. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation). J Am Coll Cardiol. 2012;60:1340-8
18. Feres F, Costa RA, Abizaid A, et al. Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial. JAMA. 2013;310:2510-22
19. Collet J-P, Silvain J, Barthélémy O, et al. Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial. Lancet. 2014;384: 1577-85
20. Colombo A, Chieffo A, Frasheri A, et al. Second-generation drugeluting stent implantation followed by 6-versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial. J Am Coll Cardiol. 2014;64:2086-97
21. Gilard M, Barragan P, Noryani AAL, et al. 6-versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial. J Am Coll Cardiol 2015;65:777-86
22. Schulz-Schüpke S, Byrne RA, ten Berg JM, et al. ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. Eur Heart J. 2015;36:1252-63
23. Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual-antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371:2155-66
24. Helft G, Steg PG, Le Feuvre C, et al. Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial. Eur Heart J. 2016;37:365-74
25. Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372:1791-800
26. Committee on Standards for Systematic Reviews of Comparative Effectiveness Research. Institute of Medicine (US). Finding What Works in Health Care: Standards for Systematic Reviews. Washington, DC: National Academies Press; 2011
27. Jacobs AK, Kushner FG, Ettinger SM, et al. ACCF/AHA clinical practice guideline methodology summit report: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;127:268-310
28. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health Care Evaluations. Hoboken, NJ: Wiley; 2004
29. Kereiakes DJ, Yeh RW, Massaro JM, et al. Antiplatelet therapy duration following bare metal or drug-eluting coronary stents: the Dual Antiplatelet Therapy randomized clinical trial. JAMA. 2015;313:1113-21
30. He Y, Bittl JA, Wouhib A, et al. Case study in cardiovascular medicine: unprotected left main coronary artery disease. In: Biondi-Zoccai G, ed. Network Meta-Analysis: Evidence Synthesis With Mixed Treatment Comparison. Hauppauge, NY: Nova Science Publishers, Inc.; 2014:285-386
31. Carlin BP, Louis TA, Carlin BP. Bayesian Methods for Data Analysis. 3rd ed. Boca Raton, FL: CRC Press; 2009
32. Kruschke JK. Doing Bayesian Data Analysis: A Tutorial With R and BUGS. Burlington, MA: Academic Press; 2010
33. Bhatt DL, Flather MD, Hacke W, et al. Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49:1982-8
34. Schwarzer G. Package 'meta'. Freiburg, Germany: version 3.8-0, 2012
35. Lunn D, Jackson C, Best N, et al. The BUGS Book: A Practical Introduction to Bayesian Analysis. Boca Raton, FL: CRC Press, Taylor &Francis Group; 2013
36. Thomas A, O'Hara B, Ligges U, et al. Making BUGS open. R News. 2006:12-7
37. Cates CJ. Simpson's paradox and calculation of number needed to treat from meta-analysis. BMC Med Res Methodol. 2002;2:1-4
38. Bittl JA. Dual-antiplatelet therapy for diabetic patients after stent implantation: lessons from an observational study. J Am Coll Cardiol. 2015;66:1102-4
39. Collet J-P, Cuisset T, Rangé G, et al. Bedside monitoring to adjust antiplatelet therapy for coronary stenting. N Engl J Med. 2012;367:2100-9
40. The early termination of clinical trials: causes, consequences, and control. With special reference to trials in the field of arrhythmias and sudden death. Task Force of the Working Group on Arrhythmias of the European Society of Cardiology. Circulation. 1994;89:2892-907
41. Piantadosi S. Stopping considerations. In: Clinical Trials: A Methodologic Perspective. New York, NY: Wiley-Interscience; 1997:230-69
42. Bhatt DL, Fox KAA, Hacke W, et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med. 2006;354:1706-17
43. Yeh RW, Kereiakes DJ, Steg PG, et al. Benefits and risks of extended duration dual antiplatelet therapy after PCI in patients with and without acute myocardial infarction. J Am Coll Cardiol. 2015;65:2211-21
44. Udell JA, Bonaca MP, Collet J-P et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. Eur Heart J. 2016;37:390-9
45. Elmariah S, Mauri L, Doros G, et al. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis (erratum in Lancet. 2015;355;1834). Lancet. 2015;385:792-8
46. US Food and Drug Administration. (November 6, 2015) Plavix (clopidogrel): drug safety communication-long-term treatment does not change risk of death. Available at: http://www.fda.gov/ Safety/MedWatch/SafetyInformation/SafetyAlertsforHuman MedicalProducs/ucm471531.htm. Accessed February 24, 2016
47. Moussa I, Oetgen M, Roubin G, et al. Effectiveness of clopidogrel and aspirin versus ticlopidine and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation. 1999;99:2364-6
48. Bertrand ME, Rupprecht HJ, Urban P, et al. Double-blind study of the safety of clopidogrel with and without a loading dose in combination with aspirin compared with ticlopidine in combination with aspirin after coronary stenting: the Clopidogrel Aspirin Stent International Cooperative Study (CLASSICS). Circulation. 2000;102:624-9
49. Steinhubl SR, Berger PB, Mann JT, 3rd et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002;288:2411-20
50. Daemen J, Wenaweser P, Tsuchida K, et al. Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet. 2007;369:667-78
51. Kleiman NS. Grabbing the horns of a dilemma: the duration of dual antiplatelet therapy after stent implantation. Circulation. 2012;125:1967-70
52. Pfisterer M, Kaiser C, Jeger R. No one-size-fits-all: a tailored approach to antithrombotic therapy after stent implantation. Circulation. 2012;125:471-3
53. Witzenbichler B. Dual antiplatelet therapy after drug-eluting stent implantation: is it time to slacken the reins? J Am Coll Cardiol. 2012;60:1349-51
54. Holmes DR Jr. Art and science. J Am Coll Cardiol. 2014;64:2098-100
55. Colombo A, Chieffo A. Dual antiplatelet therapy after drugeluting stents-how long to treat? N Engl J Med. 2014;371: 2225-6
56. Binder RK, Lüscher TF. Duration of dual antiplatelet therapy after coronary artery stenting: where is the sweet spot between ischaemia and bleeding? Eur Heart J. 2015;36:1207-11
57. Keaney JF. Balancing the risks and benefits of dual platelet inhibition. N Engl J Med. 2015;372:1854-6
58. Diamond GA, Kaul S. Prior convictions: Bayesian approaches to the analysis and interpretation of clinical megatrials. J Am Coll Cardiol. 2004;43:1929-39
59. Goodman SN. Toward evidence-based medical statistics. 1: the P value fallacy. Ann Intern Med. 1999;130:995-1004
60. Meinert CL, Tonascia S. Patient follow-up, close-out, and post-trial follow-up. In: Clinical Trials: Design, Conduct, and Analysis. New York, NY: Oxford University Press; 1986:159-65
61. Morey-Vargas OL, Zeballos-Palacios OL, Gionfriddo MR, et al. The hierarchy of evidence. In: Biondi-Zoccai G, ed. Network Meta-Analysis: Evidence Synthesis With Mixed Treatment Comparison. Hauppauge, NY: Nova Science Publishers, Inc.; 2014:3-20
62. Spencer FA, Prasad M, Vandvik PO, et al. Longer-versus shorterduration dual-antiplatelet therapy after drug-eluting stent placement: a systematic review and meta-analysis. Ann Intern Med. 2015;163:118-26
63. Navarese EP, Andreotti F, Schulze V, et al. Optimal duration of dual antiplatelet therapy after percutaneous coronary intervention with drug eluting stents: meta-analysis of randomised controlled trials. BMJ. 2015;350:h1618
64. Montalescot G, Brieger D, Dalby AJ, et al. Duration of dual antiplatelet therapy after coronary stenting: a review of the evidence. J Am Coll Cardiol. 2015;66:832-47
65. Meinert CL, Tonascia S. Questions concerning the design, analysis, and interpretation of clinical trials. In: Clinical Trials: Design, Conduct, and Analysis. New York, NY: Oxford University Press; 1986:196-207
66. Claessen BE, Henriques JPS, Jaffer FA, et al. Stent thrombosis: a clinical perspective. JACC Cardiovasc Interv. 2014;7:1081-92
67. Lasala JM, Cox DA, Dobies D, et al. Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries. Circ Cardiovasc Interv. 2009;2:285-93
68. Hermiller JB, Krucoff MW, Kereiakes DJ, et al. Benefits and risks of extended dual antiplatelet therapy after everolimus-eluting stents. JACC Cardiovasc Interv. 2016;9:138-47
69. Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med. 2007;357:2482-94
70. Sabatine MS, Cannon CP, Gibson CM, et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for mycocardial infarction with ST-segment elevation. N Engl J Med. 2005;352:1179-89
71. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without STsegment elevation. N Engl J Med. 2001;345:494-502
72. Amsterdam EA, Wenger NK, Brindis RG et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;130:e344-426